StockMirror — Stock Screener

TATVA Q1 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Tatva Chintan Pharma Chem reported a strong Q1 FY27 with revenue up 43% YoY and EBITDA up 86% YoY. Growth was broad-based across all segments (PTC, SDA, PASC, Electrolyte Salts). Key highlights include the successful qualification of its first semiconductor chemical batch, the approval of a new INR 200 crore greenfield facility, and reaffirmed FY27 guidance of 25-30% revenue growth and 20-22% EBITDA margins. Risks include geopolitical disruptions to raw material supply (affecting Electrolyte Salts) and aggressive Chinese pricing in certain product lines. The outlook is positive, underpinned by Euro 7 tailwinds, new product commercializations, and capacity expansion plans. , , ,

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management is pursuing aggressive volume-led growth (25-30% revenue) while maintaining healthy EBITDA margins (20-22%) through operating leverage and price pass-through. The new capex is aimed at enabling further growth without explicitly sacrificing margin goals. ,

About Tatva Chintan Pharma Chem Limited

Tatva Chintan Pharma Chem Limited (TATVA) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More